Esomeprazole Magnesium
(Synonyms: 埃索美拉唑镁,(S)-Omeprazole magnesium; (-)-Omeprazole magnesium) 目录号 : GC14313
A form of esomeprazole in complex with magnesium
Cas No.:161973-10-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Esomeprazole magnesium is an inhibitor of H+, K+-ATPase, effectively used in the research of upper intestinal disorder.
Esomeprazole magnesium is an inhibitor of H+, K+-ATPase[1].
Esomeprazole magnesium (0.5, 5, 50 mg/kg/day, p.o.) produces increased gastric total antioxidant capacity, decreases gastric lipid peroxide levels, significantly increases superoxide dismutase levels, but shows no obvious effect on colonic lipid peroxide levels in mice[1].
References:
[1]. Koch TR, et al. Effect of the H, K-ATPase inhibitor, esomeprazole magnesium, on gut total antioxidant capacity in mice. J Nutr Biochem. 2004 Sep;15(9):522-6.
Animal experiment: | Mice[1]In this 10-day supplementation experiment, mice (n = 10/group) receive the following: 1) as a control group, only the vehicle for dissolution of Esomeprazole (PEG-400) given orally once daily by gastric gavage; 2) Esomeprazole 0.5 mg/kg in an equivalent volume of PEG-400 given orally once daily by gastric lavage; 3) Esomeprazole 5 mg/kg in an equivalent volume of PEG-400 given orally once daily by gastric lavage; and 4) Esomeprazole 50 mg/kg in an equivalent volume of PEG-400 given orally once daily by gastric lavage[1]. |
References: [1]. Koch TR, et al. Effect of the H, K-ATPase inhibitor, esomeprazole magnesium, on gut total antioxidant capacity in mice. J Nutr Biochem. 2004 Sep;15(9):522-6. | |
| Cas No. | 161973-10-0 | SDF | |
| 别名 | 埃索美拉唑镁,(S)-Omeprazole magnesium; (-)-Omeprazole magnesium | ||
| 化学名 | magnesium;5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide | ||
| Canonical SMILES | CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.[Mg+2] | ||
| 分子式 | C34H36MgN6O6S2 | 分子量 | 713.12 |
| 溶解度 | ≥ 20.15mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4023 mL | 7.0114 mL | 14.0229 mL |
| 5 mM | 0.2805 mL | 1.4023 mL | 2.8046 mL |
| 10 mM | 0.1402 mL | 0.7011 mL | 1.4023 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet